OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece
C. Tzanetakos, George Gourzoulidis
Value in Health Regional Issues (2023) Vol. 36, pp. 18-26
Open Access | Times Cited: 17
C. Tzanetakos, George Gourzoulidis
Value in Health Regional Issues (2023) Vol. 36, pp. 18-26
Open Access | Times Cited: 17
Showing 17 citing articles:
Immune checkpoint inhibitors versus chemotherapy as second-line therapy for advanced oesophageal squamous cell carcinoma: a systematic review and economic evaluation
Shixian Liu, Lei Dou, Shunping Li
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 6
Shixian Liu, Lei Dou, Shunping Li
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 6
Cervical cancer screening by cotesting method for Vietnamese women 25–55 years old: a cost-effectiveness analysis
Hien Bui, Van Nu Hanh Pham, Thang Hong Vu
BMJ Open (2025) Vol. 15, Iss. 1, pp. e082145-e082145
Open Access
Hien Bui, Van Nu Hanh Pham, Thang Hong Vu
BMJ Open (2025) Vol. 15, Iss. 1, pp. e082145-e082145
Open Access
Does Real-World Evidence of the Economic Burden of Lung Cancer in Greece Exist? A Systematic Review of the Literature
George Gourzoulidis, Catherine Kastanioti, George Mavridoglou, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 130-130
Open Access
George Gourzoulidis, Catherine Kastanioti, George Mavridoglou, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 130-130
Open Access
Cost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in Greece
C. Tzanetakos, M Psarra, Ilias Kotsis, et al.
Value in Health Regional Issues (2025) Vol. 46, pp. 101091-101091
Open Access
C. Tzanetakos, M Psarra, Ilias Kotsis, et al.
Value in Health Regional Issues (2025) Vol. 46, pp. 101091-101091
Open Access
Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
George Gourzoulidis, Myrto Barmpouni, Vasiliki Kossyvaki, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 8
George Gourzoulidis, Myrto Barmpouni, Vasiliki Kossyvaki, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 8
A European Cost–Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes
Johan Jendle, Maria Ida Buompensiere, Asli Zeynep Ozdemir Saltik, et al.
Diabetes Technology & Therapeutics (2023) Vol. 25, Iss. 12, pp. 864-876
Closed Access | Times Cited: 7
Johan Jendle, Maria Ida Buompensiere, Asli Zeynep Ozdemir Saltik, et al.
Diabetes Technology & Therapeutics (2023) Vol. 25, Iss. 12, pp. 864-876
Closed Access | Times Cited: 7
The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China
Zhanjing Dai, Jiayi Xu, Feng Chang, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 2
Zhanjing Dai, Jiayi Xu, Feng Chang, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 2
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma
Jinhong Gong, Jingjing Shang, Dan Su, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 23, Iss. 6, pp. 709-717
Closed Access | Times Cited: 5
Jinhong Gong, Jingjing Shang, Dan Su, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 23, Iss. 6, pp. 709-717
Closed Access | Times Cited: 5
Long-Term Cost-Effectiveness of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Adults With Type 1 Diabetes in Iran
Mohsen Choband Molaee, Zahra Gharib Naseri, Masoud Ali Karami
Value in Health Regional Issues (2024) Vol. 43, pp. 101002-101002
Closed Access | Times Cited: 1
Mohsen Choband Molaee, Zahra Gharib Naseri, Masoud Ali Karami
Value in Health Regional Issues (2024) Vol. 43, pp. 101002-101002
Closed Access | Times Cited: 1
Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China
Shuo Kang, Xiaohui Wang, Zhenhua Pan, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 24, Iss. 2, pp. 285-292
Closed Access | Times Cited: 2
Shuo Kang, Xiaohui Wang, Zhenhua Pan, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 24, Iss. 2, pp. 285-292
Closed Access | Times Cited: 2
Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece
George Gourzoulidis, Argyro Solakidi, M Psarra, et al.
Clinical Drug Investigation (2023) Vol. 44, Iss. 1, pp. 59-69
Closed Access | Times Cited: 2
George Gourzoulidis, Argyro Solakidi, M Psarra, et al.
Clinical Drug Investigation (2023) Vol. 44, Iss. 1, pp. 59-69
Closed Access | Times Cited: 2
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
Shuo Kang, Jintuo Yin
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 5, pp. 653-659
Closed Access
Shuo Kang, Jintuo Yin
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 5, pp. 653-659
Closed Access
Cost-effectiveness analysis of trifluridine/tipiracil in the treatment of heavily pretreated metastatic gastric cancer from the perspective of Chinese healthcare system
Ying Ting, Ran Xia, Yuanyuan Zhang, et al.
BMJ Open (2024) Vol. 14, Iss. 11, pp. e080846-e080846
Open Access
Ying Ting, Ran Xia, Yuanyuan Zhang, et al.
BMJ Open (2024) Vol. 14, Iss. 11, pp. e080846-e080846
Open Access
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece
George Gourzoulidis, Oresteia Zisimopoulou, Andrianos Liavas, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 24, Iss. 3, pp. 375-385
Closed Access | Times Cited: 1
George Gourzoulidis, Oresteia Zisimopoulou, Andrianos Liavas, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 24, Iss. 3, pp. 375-385
Closed Access | Times Cited: 1
Cost–effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer
Ruizhe Liu, Yijia Zhao, Fenghao Shi, et al.
Immunotherapy (2024) Vol. 16, Iss. 10, pp. 669-678
Closed Access
Ruizhe Liu, Yijia Zhao, Fenghao Shi, et al.
Immunotherapy (2024) Vol. 16, Iss. 10, pp. 669-678
Closed Access
Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece
George Gourzoulidis, C. Tzanetakos, Argyro Solakidi, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1232-1232
Open Access
George Gourzoulidis, C. Tzanetakos, Argyro Solakidi, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1232-1232
Open Access
Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
ClinicoEconomics and Outcomes Research (2023) Vol. Volume 15, pp. 739-752
Open Access
Jas Bindra, Ishveen Chopra, Kyle Hayes, et al.
ClinicoEconomics and Outcomes Research (2023) Vol. Volume 15, pp. 739-752
Open Access
